Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis by Martinez-Ramirez, Daniel et al.
Articles
Comparable Botulinum Toxin Outcomes between Primary and Secondary
Blepharospasm: A Retrospective Analysis
Daniel Martinez-Ramirez
1




, Aparna Wagle Shukla
1
, Irene A. Malaty
1





1Department of Neurology, Center for Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, USA, 2Department of Neurosurgery,
Center for Movement Disorders and Neurorestoration, University of Florida, Gainesville, FL, USA
Abstract
Background: Blepharospasm is a focal cranial dystonia, which could be idiopathic in origin or secondary to an underlying disorder that commonly impairs quality
of life. Botulinum toxin (BoNT) injections have become the treatment of choice; however, a less favorable response to BoNT is expected in secondary
blepharospasm. No studies have been conducted comparing outcomes between blepharospasm cohorts. We therefore aim to compare BoNT outcomes in primary
and secondary blepharospasm subjects.
Methods: A retrospective review of 64 blepharospasm subjects receiving BoNT therapy was conducted. Demographics, BoNT treatment schedules, duration of
BoNT therapy, and side effects were recorded. Outcome measures were duration of benefit, peak-dose benefit recorded with the Clinical Global Impressions Scale
(CGIS), and related side effects.
Results: No difference was found between the two cohorts regarding duration of benefit from treatment (primary 9.47 weeks vs. secondary 9.63 weeks, p50.88).
Perceived peak-dose benefit was more commonly reported as ‘‘very much improved’’ in secondary patients, but this was not significant (p50.13). Higher BoNT
dosages were required in both groups over time, with a mean increase of 20.5% in primary and 26.5% in secondary blepharospasm. Ptosis (8%) and diplopia (6%)
were the most common reported side effects. Mean follow-up in years was similar between groups, 3.6 years for primary vs. 2.4 years for secondary blepharospasm
(p50.17).
Discussion: BoNT injections were effective with comparable benefits seen in both primary and secondary blepharospasm populations. Clinicians should be aware
of the similar benefit from BoNT reported in secondary blepharospasm patients. The average duration of benefit in this cohort was comparable with previous
reports.
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Introduction
Blepharospasm is a focal dystonia characterized by involuntary
eyelid closure due to overactivity of the orbicularis oculi, the
corrugators, and the procerus muscles.1 The primary or idiopathic
form, occasionally referred as benign essential blepharospasm, is the
most frequent subtype.2 Blepharospasm may also be a manifestation of
another underlying organic disorder. Secondary blepharospasm has
been reported most commonly in structural brain lesions,3 tardive
syndromes due to medication exposure,4 or related to neurodegen-
erative disorders, in particular Parkinson’s disease (PD) and other
parkinsonian syndromes.5
Blepharospasm is unlikely to be self-limited and may become a
lifelong disabling condition requiring long-term treatment.1 Botulinum
toxin (BoNT) injections have become the main treatment for this and
other types of focal dystonias6 with a reported success rate of 90%.7
Studies of BoNT outcomes on secondary blepharospasm are scarce,
and there is consensus of a less favorable response to BoNT, with
reports ranging from 50% to 60% clinical improvement.8,9 No studies
have been conducted comparing outcomes between primary and
secondary blepharospasm cohorts. We therefore sought to compare
the treatment outcomes with BoNT therapy in primary and secondary
blepharospasm and to describe the factors affecting these outcomes.
In the following retrospective study, comparable results regarding
duration of benefit and perceived peak-dose benefit were observed in
primary vs. secondary blepharospasm cohorts.
Methods
Study design
A retrospective review of 275 electronic records at the University of
Florida Center for Movement Disorders and Neurorestoration (UF-
CMDNR) was conducted from the period of July 2011 to June 2014.
Daniel Martinez-Ramirez and Juan C. Giugni performed the chart
review. The UF Institutional Review Board (IRB) approved the study.
Population studied
Subjects with a clinical diagnosis of blepharospasm according to the
International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM code 333.81), which was made by specialists
trained in movement disorders, and who had received or are currently
treated in our BoNT clinic were included. Patients with uncertain
diagnosis and those with incomplete data on their electronic records
were excluded. The studied population was divided into two groups
according to the origin of blepharospasm as a primary or secondary
blepharospasm. Causes of secondary blepharospasm included tumors,
tardive syndromes, or neurodegenerative disorders, such as PD. Data
were gathered in a prospective manner into our IRB database and
analyzed retrospectively. Demographic information, BoNT treatment
schedules (muscles and units injected) from the first and last (most
recent) sessions at the UF-CMDNR, and side effects were obtained
from each patient’s record, as well as from our IRB-approved
database, INFORM-PD.
Description of procedure
Most patients received onabotulinumtoxinA (Botox, Allergan,
Irvine, CA). For patients receiving rimabotulinumtoxinB (Myobloc,
US World Meds, Louisville, KY; n53), an approximate ratio of 52.3:1
was used to calculate total dosages.10 No patients were found to be
receiving incobotulinumtoxinA or abobotulinumtoxinA. BoNT was
prepared by trained nurses using 1 mL of saline solution for dilution to
obtain 10 units in 0.1 mL for onabotulinumtoxinA. Injections were
performed by fellowship trained movement disorders specialists
experienced in this procedure.
Outcome measurements
The outcomes of the study were to compare 1) the duration of
benefit, 2) the perceived peak-dose benefit, and 3) the side effects from
BoNT injections from the first and last injections at UF between
primary vs. secondary blepharospasm cohorts. Duration of benefit was
ascertained by the following question, ‘‘How long did the benefit from
the botulinum toxin injections last?’’, which was always asked by the
clinician performing injections at each subject visit; it was reported in
weeks, and was based on an estimate recall. The perceived peak-dose
benefit from BoNT was obtained from the Clinical Global Impressions
Scale (CGIS) during each subject’s visit. The CGIS is a self-reported
seven-point scale covering measures that evaluate change after the
initiation of treatment. Subjects answer the question, ‘‘How would you
describe your peak benefit from botulinum toxin injections?’’ with the
following possible answers: 1, very much improved; 2, much improved;
3, minimally improved; 4, no change; 5, minimally worse; 6, much
worse; and 7, very much worse.11 Assessment of side effects was
performed at each patient’s visit. The clinician asked about the
following symptoms: bruising, difficulty swallowing, head drop,
headache, muscle weakness, drooping of eyelid, or upper respiratory
infection.
Statistical analysis
A x2 test corrected with an Exact test was used for the following
variables: gender, ethnicity, smoker, and muscles injected. Student’s t-
test was used for age, body mass index (BMI), years since first
symptom, years since diagnosis, follow-up duration, dosages, number
of injection sites, and side effects. To examine differences in duration
of BoNT benefit and CGIS of benefit between primary and secondary
blepharospasm, we used the independent samples t-test. p-Values
,0.05 were considered statistically significant. A univariate general
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linear model was used to compare outcomes within the secondary
blepharospasm cohort. Bonferroni-corrected p-values for multiple
comparisons are shown in Tables 1 and 2. Statistical analyses were
performed using commercially available statistical software (SPSS,
version 22.0; SPSS, Inc., Chicago, IL).
Results
Characteristics of population
Of the 64 subjects included for the final analysis, 64% (41/64) had
primary and 36% (23/64) had secondary blepharospasm. Sixty-eight
percent (28/41) in the primary blepharospasm group were females
compared with 26% (6/23) in the secondary group (x2510.5, df51,
p50.001). Mean ages at time of evaluation were 69.1 (¡9.2) years in the
primary and 65.9 (¡10.2) years in the secondary group (t521.25,
p50.22). Symptom duration was significantly longer in primary than
in secondary blepharospasm 14.2 (¡11.9) vs. 6.2 (¡4.7) (t523.1,
p50.003). Twenty-six primary blepharospasm patients had additional
areas (20 patients had oromandibular dystonia (Meige syndrome) and 6
had Meige syndrome plus cervical dystonia) affected, while all secondary
blepharospasm patients had other body regions involved. The main
causes of secondary blepharospasm included PD 52% (12/23), followed
by tardive syndromes in 26% (6/23). Other causes included progressive
supranuclear palsy in three out of 23 cases, one case of Tourette
syndrome, and one case secondary to radiotherapy. Five patients in the
primary cohort had a past history of eyelid plastic surgery but continued
to have symptoms requiring BoNT intervention. Four patients with
primary blepharospasm, and eight with secondary blepharospasm had
deep brain stimulation (DBS) implantation (df51, p50.4). Table 1
describes demographic and clinical characteristics in our population.
The clinical characteristics of the 12 PD patients in our cohort are
also described. They had disease duration of 15.8 (¡6.5) years, a
Unified Parkinson’s Disease Rating Scale-III off-medication (on
stimulation, if the case) score of 39.8 (¡13.1) and an on-medication
(on stimulation, if the case) score of 32.8 (¡9.1), Hoehn and Yahr
stage 3.25 (¡0.8), and levodopa equivalent dose of 1,367 (¡432.7).
Eight patients had DBS, and blepharospasm developed after device
implantation.
Characteristics of botulinum toxin injections
The average follow-up at our BoNT clinic was 3.6 years for the
primary group and 2.4 years for the secondary group (t521.38,
p50.17). The average dosages used in the first injection were 45.5
(¡28.4) units for the primary cohort compared with 39.3 (¡24.6)
units for the secondary cohort (t520.88, p50.38). The dosages of
the last injections were 57.2 (¡21.4) units for primary vs. 53.2
(¡21.1) units for secondary (t520.62, p50.54). A mean increase in
BoNT units of 20.5% in primary and 26.5% in secondary
blepharospasm was observed over time. We found that in both
cohorts, additional muscles (procerus, corrugators, and frontalis)
were included in the treatment plan when comparing the last
injection with the initial injection of BoNT therapy. Table 2
summarizes BoNT injections.
‘‘How long did the benefit from the botulinum toxin injections
last?’’
The primary blepharospasm group reported the duration of
benefit to be 9.3 (¡3.6) weeks from the first injection compared with
9.5 (¡3.7) for the last injection at UF. Secondary blepharospasm
subjects described the duration of benefit to be 8.2 (¡3.5) weeks
from the first injection compared with 9.6 (¡2.3) weeks from the last
injection at UF. The analysis revealed a comparable duration of
BoNT benefit from the first injections (t521.04, df551, p50.30)
and last injections (t50.15, df550, p50.88) for primary and
secondary blepharospasm.






Female, no. (%) 28 (68.3) 6 (26.1) 0.001
Age, mean (SD), years 69.1 (9.2) 65.9 (10.2) 0.22
Caucasian, no. (%) 36 (87.8) 21 (91.3) 0.32
Smoker, no. (%) 12 (29.3) 10 (43.5) 0.33
BMI, mean (SD) 26.5 (5.5) 29.3 (7) 0.13
Years since first symptom, mean (SD) 14.2 (12.1) 6.2 (4.7) ,0.001
Years since diagnosis, mean (SD) 11 (8.8) 5.7 (4) 0.002
Duration of follow-up at UF, months (SD) 42.8 (39.3) 28.6 (29.5) 0.17
BMI, Body Mass Index; SD, Standard Deviation; UF, University of Florida.
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Perceived peak-dose benefit from BoNT—CGIS
In the primary blepharospasm cohort, a similar number of patients
described the benefit as ‘‘much improved’’ (48.6% vs. 50%) and ‘‘very
much improved’’ (27% vs. 30.6%) after the first and last injections,
respectively, using the CGIS. In the secondary cohort, 43.8%
perceived the benefit as ‘‘very much improved’’ after the initial session
compared with 56.3% after the last session. The same number of
subjects (31.3%) perceived a ‘‘much improved’’ benefit in both
sessions. Figure 1 represents the perceived peak-dose benefit in our
populations. The CGIS revealed a similar magnitude of benefit for
primary and secondary blepharospasm after the first (2.1¡0.9 vs.
1.9¡0.9, t520.73, df551, p50.47) and last injections (1.9¡0.8 vs.
1.6¡0.7, t521.56, df550, p50.13). Five primary patients and one
secondary blepharospasm patient reported no benefit from the first
BoNT injections, with only one primary blepharospasm patient
reporting no change after the last injection.
Comparison within secondary blepharospasm cohort
A univariate general linear model was used to compare outcomes
within the secondary blepharospasm cohort (neurodegenerative group,
n59, vs. drug-induced group, n55). No significant differences were
observed between groups during sessions. For the first injections at UF,
the duration of benefit in weeks was 8.9¡2.9 vs. 8.2¡2.9 (df51,
p50.68) and the CGIS was 1.4¡0.7 vs. 2.2¡0.8 (df51, p50.1).
Regarding the last injections, the duration of benefit was 8.9¡2.2 vs.
11.2¡2.1 weeks (df51, p50.08) with a CGIS of 1.4¡0.8 vs. 1.8¡0.8
(df54, p50.67).
Side effects
Side effects in our cohort varied from 16.2% to 25% after the first
injection and from 5% to 17.6% after the last injection at UF. No
significance was found in frequency of side effects between the first
(x253.6, df51, p50.06) and the last sessions (x250.02, df51, p50.89)
Table 2. Comparison of BoNT Injections between First and Last Sessions at the University of Florida
Primary (n541) Secondary (n523) p
First injection
Dosage in units, mean (SD) 45.5 (28.4) 39.3 (24.6) 0.38
Shots given, mean (SD) 9.3 (2.7) 8.8 (1.8) 0.39
Side effects, no. (%) 10 (25) 1 (5) 0.02
Lateral oculi, no. (%) 41 (100) 23 (100) 1
Pretarsal, no. (%) 30 (73.2) 18 (78.3) 0.65
Corrugator, no. (%) 12 (29.3) 8 (34.8) 0.65
Procerus, no. (%) 14 (34.1) 4 (17.4) 0.15
Frontalis, no. (%) 8 (19.5) 1 (4.3) 0.14
Last injection
Dosage, mean (SD) 57.2 (21.4) 53.5 (21.1) 0.54
Shots given, mean (SD) 9.9 (2.3) 9.9 (1.9) 0.99
Side effects, no. (%) 6 (16.2) 3 (17.6) 0.89
Lateral oculi, no. (%) 37 (100) 19 (100) 1
Pretarsal, no. (%) 28 (75.7) 18 (94.7) 0.14
Corrugator, no. (%) 18 (48.6) 10 (52.6) 0.78
Procerus, no. (%) 22 (59.5) 6 (31.6) 0.05
Frontalis, no. (%) 9 (22) 2 (10.5) 0.29
BoNT, Botulinum Toxin; SD, Standard Deviation.
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in the blepharospasm cohorts. Reported side effects in the primary
blepharospasm group were as follows: first injection, bruising (three out
of 10), dry eyes (two out of 10), ptosis (two out of 10), and red eye,
diplopia, and pain, one case each; last injection – diplopia (3/6), with
bruising, dry eyes, and ptosis one case each. Only one subject in the
secondary blepharospasm group reported bruising after the first
injections, and three reported bruising after the last injections.
Discussion
In the present study, treatment outcomes of BoNT injections were
compared between primary and secondary blepharospasm. Primary
blepharospasm was found to be more prevalent in females, whereas
secondary blepharospasm was more common in males. These findings
are consistent with previous reports,5,12,13 where focal cranial dystonias
have been reported to be more prevalent in females; since the majority
of secondary causes in our cohort were due to PD (52%), which is male
predominant, this gender predominance is expected as well. Both
populations had a similar mean age of onset for symptoms in the sixth
decade of life, which is expected since blepharospasm is known to
present as a late-onset disease.12–15 Among the etiologies of secondary
blepharospasm, PD was found to be the most common, followed by
tardive syndrome. This contrasts with other studies,5,13 which have
reported predominance of atypical parkinsonisms among the causes of
secondary blepharospasm. Interestingly, eight of 12 PD patients in our
cohort had DBS, with the development of blepharospasm after device
implantation, which could also potentially explain the unusual number
of secondary blepharospasm cases related to idiopathic PD. Employing
different methodologies, which included other cranial dystonias, and a
lack of inclusion of patients with apraxia of eyelid opening could
explain this difference.
We also observed a significant delay in diagnosis for patients with
primary blepharospasm compared with secondary blepharospasm.
One possibility could be the fact that patients with secondary causes,
particularly patients with PD, would likely be under clinical
surveillance by a neurologist with more opportunities for frequent
clinical assessments.
The duration of benefit from BoNT injections was comparable
between primary and secondary cohorts. More interestingly, the
approximate reported benefit in both populations lasted for a mean of
9.5 weeks, which is below the typical 12-week injection schedule. Most
studies have reported duration of treatment efficacy ranging from 12 to
18 weeks.14–17 However, recent studies have reported lesser duration
of benefit as well. In one study of 32 patients with either
blepharospasm or hemifacial spasm, for 1.1% of the injections the
duration of benefit was reported to be less than 4 weeks.18 Another
study reported that the duration of benefit in nine blepharospasm
patients was between 9 and 13 weeks,19 similar to our findings. A
recent study of 288 blepharospasm patients reported a therapeutic
effect lasting for about 10 weeks, 2 weeks shorter than the
recommended inter-injection interval.20 Most studies have included
different types of cranial dystonia, which could also affect the results by
incorporating higher cumulative BoNT doses per injection cycle. Our
study is the first to compare the duration of benefit in subjects with
pure blepharospasm, rather than in a mixed dystonia population.
Comparable with previous studies,16 a better efficacy of BoNT
injections following the last injection was observed in both cohorts
when compared with the initial injection. This difference may have
been due to the escalation of dose and refinement of muscle
distribution of the toxin over time. An alternative explanation is that
there may have been a propensity for better benefit when muscles were
Figure 1. Chart Demonstrating the Clinical Global Impression Scale between Populations at two time points. 1) First session primary blepharospasm; 2)
last session primary blepharospasm; 3) first session secondary blepharospasm; 4) last session secondary blepharospasm.
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repeatedly subjected to treatment, rather than remaining in the native
dystonic state. Patients with secondary blepharospasm tended to report
a greater level of improvement than primary blepharospasm patients,
but this comparison did not reach significance. Furthermore, patients
who are responders are more likely to continue with serial injections,
so the last injections recorded may select for a pool of better
responders, demonstrating improved efficacy. When analyzing the
secondary cohort, we observed a shorter duration of benefit in weeks,
which was not significant, in the neurodegenerative group when
compared with the drug-induced group (8.9¡2.2 vs. 11.2¡2.1).
Although this confirms the consensus of a less favorable clinical
outcome in blepharospasm due to neurodegenerative diseases when
compared with other secondary causes, studies with a higher number
of patients will be required to confirm this observation.
A higher BoNT dose was used in both populations over time
(ranging from an increase of 11.7 to 13.9 units over 2.4–3.6 years’
follow-up), which is consistent with previous publications. In a study
measuring the long-term efficacy of BoNT in several types of dystonia,
the dosage was found to have been increased gradually.16 A recent
study of long-term treatment in cranial dystonias reported a higher
mean injection dose per visit during the last year than in the first year
of injections.15 However, another study of cranial dystonias reported
the dose required for treatment remained unchanged, suggesting that
dose changes over time might have been an effect of the ‘‘titration’’
phase, and not of increasing resistance to BoNT.14 Larger prospective
trials will be required to answer whether the increase in dose
requirements was due to the methodology employed, to disease
progression, or to progressive treatment tolerance.
Side effects in our cohort varied from 5% to 25%, with ptosis (8%)
and diplopia (6%) being the most common. This is similar to previous
studies that reported side effects ranging from 2% to 35%.14–16,18,19
Interestingly, the side effects were more significant during the first
injections in primary blepharospasm patients, perhaps because a
higher dosage was used in this cohort. The initial dosages in our
populations are higher than the recommended initial dosages;21
however, a number of our initial BoNT schedules are based on
previous treatments received outside our clinic. No previous studies
have reported the relationship between the muscles injected and the
clinical outcomes. We observed a non-significant difference in self-
described benefit from BoNT in patients receiving higher dosages on
the first visit and in those receiving injections in the corrugator muscle.
Several limitations should be considered before interpreting our
results. It is a retrospective study with a relatively small cohort.
Different trained specialists injected patients. In the first session at UF,
five different physicians injected the primary blepharospasm cohort
while four injected the secondary cohort. Three physicians injected
both cohorts in their last session. A variation in techniques could affect
the response to BoNT. We did not consider the effect of the initial
‘‘titration’’ phase distinctly from gradual increases over time; however,
our follow-up period in both cohorts is over 2 years. We did not use
clinical rating scales, such as the Jankovic Rating Scale,22 or the
Blepharospasm Disability Index23 for the assessment of severity or
disability related to blepharospasm. This study did not include
obligatory neuroimaging (magnetic resonance imaging or computed
tomography angiogram) to rule out structural brain lesions as a
secondary cause; however, no signs or symptoms were found during
clinical examination that suggested a structural brain lesion in the
primary cohort. Finally, medication adjustments could also have
affected the results. The doses of neuroleptics were held constant
during BoNT treatment for the two patients who were receiving this
class of drugs. Three patients received medications to treat tardive
dystonia (tetrabenazine or anticholinergics), and five patients had other
body regions affected by dystonia (four with cervical and one with
generalized dystonia). Doses of dopaminergic medications were
modified in five of 12 PD patients during the time of the BoNT
injections. All of these factors should be considered when interpreting
the results of our study.
In summary, BoNT injections were effective and had similar
benefits in both groups of patients, suggesting that the etiology of
blepharospasm does not seem to impact the BoNT outcome. However,
we need to consider a possible shorter duration of benefit in cranial
dystonias, specifically in blepharospasm subjects, compared with a
typical 12-week treatment cycle for cervical dystonia.24 These findings
should be of interest to practitioners injecting patients who have
blepharospasm, especially those injecting patients who have secondary
blepharospasm.
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